Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 1458-1461, 2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-717508
ABSTRACT
Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Radiothérapie
/
Sarcomes
/
Traitement médicamenteux
/
Immunothérapie
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Cancer Research and Treatment
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS